SCIENTIFIC CONSENSUS IS THAT THERE IS NO CONSISTENT OR RELIABLE EVIDENCE THAT RANITIDINE INCREASES THE RISK OF ANY CANCER

Zantac, also known as ranitidine, is a commonly used medication for heartburn and stomach ulcers. In recent years, concerns have been raised about the potential for Zantac to contain the impurity NDMA (N-Nitrosodimethylamine), which is classified as a probable human carcinogen. This led to a legal case in the United States, with plaintiffs alleging that the presence of NDMA in Zantac causes cancer. However, the court has now dismissed all of these cases. The decision was based on the results of 12 epidemiological studies, which found no consistent or reliable evidence that Zantac increases the risk of cancer. GSK, the manufacturer of Zantac, welcomed the court's ruling and said it will continue to defend itself against all claims brought at the state level.

References: https://www.gsk.com/en-gb/media/press-releases/statement-zantac-litigation/